Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine, today announced the launch ...
Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and ...
Resource drilling at PTR Minerals’ Rosewood Titanium project in South Australia’s Gawler Craton has returned some of the ...
Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...
EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...
Deep-learning analysis of routine H&E slides accurately predicts key NSCLC driver mutations, supporting treatment in lung cancer care.
Cancer patients paid the same premium, but phone calls allegedly unlocked extra approvals for some, forcing others into ...
Patients and medical professionals say the guidelines listed in the Gazette are being varied depending on who you know at SHA ...
Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results